nitrates has been researched along with Diabetic Angiopathies in 15 studies
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The effect of pioglitazone on composite endpoints was evaluated, including all-cause death, myocardial infarction (MI), and stroke, as well as safety events of edema and serious heart failure, in subgroups using nitrates, RAS blockers, or insulin at baseline." | 5.14 | Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). ( Charbonnel, B; Erdmann, E; Spanheimer, R, 2010) |
| "Organic nitrates represent a class of drugs which are clinically used for treatment of ischemic symptoms of angina as well as for congestive heart failure based on the idea to overcome the impaired NO bioavailability by "NO" replacement therapy." | 2.46 | Organic nitrates and nitrate resistance in diabetes: the role of vascular dysfunction and oxidative stress with emphasis on antioxidant properties of pentaerithrityl tetranitrate. ( Daiber, A; Oelze, M; Schuhmacher, S, 2010) |
| "Moreover, in IDDM patients reduced nitrate/nitrite excretion was strongly associated with elevated plasmatic beta-thromboglobulin levels." | 1.30 | The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. ( Huszka, M; Kaplar, M; Laszlo, P; Palatka, K; Rejto, L; Tornai, I; Udvardy, M, 1997) |
| " This study, taken with previous observations, suggests that factors other than diminished basal NO production, such as reduced bioavailability of NO probably due to the augmented production of superoxide anion with subsequently increased inactivation of NO, contribute to the high incidence of vascular disease in patients with noninsulin-dependent diabetes mellitus." | 1.30 | Basal nitric oxide production is not reduced in patients with noninsulin-dependent diabetes mellitus. ( Andreoni, S; Carotta, M; Carzaniga, G; Catalano, M; Jun, T; Perilli, E; Scandale, G, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Tian, R | 1 |
| Peng, R | 1 |
| Yang, Z | 1 |
| Peng, YY | 1 |
| Lu, N | 1 |
| Adedayo, A | 1 |
| Eluwole, A | 1 |
| Tedla, F | 1 |
| Kremer, A | 1 |
| Mastrogiovanni, N | 1 |
| Khan, M | 1 |
| Rosenberg, C | 1 |
| Dreizen, P | 1 |
| La Rosa, J | 1 |
| Salciccioli, L | 1 |
| Boutjdir, M | 1 |
| Banerji, MA | 1 |
| Brown, C | 1 |
| Salifu, M | 1 |
| Lazar, J | 1 |
| Bakillah, A | 1 |
| Bhardwaj, P | 1 |
| Khanna, D | 1 |
| Balakumar, P | 1 |
| Matsumoto, T | 1 |
| Nakayama, N | 1 |
| Ishida, K | 1 |
| Kobayashi, T | 1 |
| Kamata, K | 1 |
| Erdmann, E | 1 |
| Spanheimer, R | 1 |
| Charbonnel, B | 1 |
| Oelze, M | 1 |
| Schuhmacher, S | 1 |
| Daiber, A | 1 |
| Hermo, R | 1 |
| Mier, C | 1 |
| Mazzotta, M | 1 |
| Tsuji, M | 1 |
| Kimura, S | 1 |
| Gugliucci, A | 1 |
| Cai, L | 1 |
| Hayashi, T | 1 |
| Juliet, PA | 1 |
| Miyazaki-Akita, A | 1 |
| Funami, J | 1 |
| Matsui-Hirai, H | 1 |
| Fukatsu, A | 1 |
| Iguchi, A | 1 |
| Bassand, JP | 1 |
| Hamm, CW | 1 |
| Ardissino, D | 1 |
| Boersma, E | 1 |
| Budaj, A | 1 |
| Fernández-Avilés, F | 1 |
| Fox, KA | 1 |
| Hasdai, D | 1 |
| Ohman, EM | 1 |
| Wallentin, L | 1 |
| Wijns, W | 1 |
| Fava, S | 1 |
| Azzopardi, J | 1 |
| Agius-Muscat, H | 1 |
| Huszka, M | 1 |
| Kaplar, M | 1 |
| Rejto, L | 1 |
| Tornai, I | 1 |
| Palatka, K | 1 |
| Laszlo, P | 1 |
| Udvardy, M | 1 |
| Catalano, M | 1 |
| Carzaniga, G | 1 |
| Perilli, E | 1 |
| Jun, T | 1 |
| Scandale, G | 1 |
| Andreoni, S | 1 |
| Carotta, M | 1 |
| De Vriese, AS | 1 |
| Stoenoiu, MS | 1 |
| Elger, M | 1 |
| Devuyst, O | 1 |
| Vanholder, R | 1 |
| Kriz, W | 1 |
| Lameire, NH | 1 |
| Marfella, R | 1 |
| Quagliaro, L | 1 |
| Nappo, F | 1 |
| Ceriello, A | 1 |
| Giugliano, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow[NCT03654157] | 1,576 participants (Actual) | Observational | 2018-03-25 | Completed | |||
| Rivaroxaban Evaluation in Real Life Settings[NCT02444221] | 5,278 participants (Actual) | Observational [Patient Registry] | 2015-07-01 | Completed | |||
| Analgesia of Acute Coronary Syndromes With ST-segment Elevation in a Pre-hospital Setting. Randomized Non-inferiority Trial of the Association MEOPA + Paracetamol Versus Morphine.[NCT02198378] | Phase 4 | 680 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia[NCT01797484] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Relativ acceleration or deceleration (1/s) of left ventricular myocardial sections compared to direct opposite section. The more positive the value, the more simultaneously the movements, the more hemodynamically better. (NCT01797484)
Timeframe: 42 days after first dose of Ranolazine
| Intervention | percentage of change (Mean) |
|---|---|
| Ranolazine | 18 |
| No Additional Medication | 23 |
2 reviews available for nitrates and Diabetic Angiopathies
| Article | Year |
|---|---|
Organic nitrates and nitrate resistance in diabetes: the role of vascular dysfunction and oxidative stress with emphasis on antioxidant properties of pentaerithrityl tetranitrate.
Topics: Animals; Antioxidants; Diabetic Angiopathies; Drug Resistance; Endothelium, Vascular; Humans; Nitrat | 2010 |
Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy.
Topics: Cardiomyopathies; Diabetes Mellitus; Diabetic Angiopathies; Humans; Metallothionein; Nitrates; Nitro | 2006 |
1 trial available for nitrates and Diabetic Angiopathies
| Article | Year |
|---|---|
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
Topics: Age of Onset; Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic An | 2010 |
12 other studies available for nitrates and Diabetic Angiopathies
| Article | Year |
|---|---|
Supplementation of dietary nitrate attenuated oxidative stress and endothelial dysfunction in diabetic vasculature through inhibition of NADPH oxidase.
Topics: Administration, Oral; Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Angiopathies; | 2020 |
Association between nitrated lipoproteins and vascular function in type 2 diabetes.
Topics: Aged; Biomarkers; Blood Vessels; Case-Control Studies; Cholesterol, HDL; Diabetes Mellitus, Type 2; | 2021 |
Catechin averts experimental diabetes mellitus-induced vascular endothelial structural and functional abnormalities.
Topics: Animals; Aorta; Blood Glucose; Catechin; Cytoprotection; Diabetes Mellitus, Experimental; Diabetic A | 2014 |
Eicosapentaenoic acid improves imbalance between vasodilator and vasoconstrictor actions of endothelium-derived factors in mesenteric arteries from rats at chronic stage of type 2 diabetes.
Topics: Animals; Blood Chemical Analysis; Blood Pressure; Blotting, Western; Chronic Disease; Diabetes Melli | 2009 |
Circulating levels of nitrated apolipoprotein A-I are increased in type 2 diabetic patients.
Topics: Aged; Apolipoprotein A-I; Arteriosclerosis; Biomarkers; Case-Control Studies; Diabetes Complications | 2005 |
beta1 antagonist and beta2 agonist, celiprolol, restores the impaired endothelial dependent and independent responses and decreased TNFalpha in rat with type II diabetes.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Aorta, Abdomin | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Blo | 2007 |
Outcome of unstable angina in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angioplasty; Aspirin; Calcium Channel Blockers; | 1997 |
The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus.
Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes | 1997 |
Basal nitric oxide production is not reduced in patients with noninsulin-dependent diabetes mellitus.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Male; | 1997 |
Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide.
Topics: Animals; Blood Vessels; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathi | 2001 |
Acute hyperglycemia induces an oxidative stress in healthy subjects.
Topics: Adult; Biomarkers; Confounding Factors, Epidemiologic; Diabetic Angiopathies; Female; Glucose Clamp | 2001 |